GlassScriptPhysician profile
Melissa I Costner
NPI 1265491302
$903,655.95
in general payments reported to CMS, 2019-2025
41 companies · $220K in 2025
The $220K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $30K · 2021: $61K · 2022: $161K · 2023: $131K · 2024: $179K · 2025: $220K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $334K · Consulting Fee: $128K · Travel and Lodging: $41K · Food and Beverage: $20K · Honoraria: $7,200 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $333,782.50 |
| Consulting Fee | $127,694.50 |
| Travel and Lodging | $41,155.80 |
| Food and Beverage | $19,882.22 |
| Honoraria | $7,200.00 |
| Education | $271.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $421,044.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $223,103.47 | 2019-2025 | Dupixent |
| Abbvie INC. | $127,125.48 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $67,036.17 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $27,730.58 | 2023-2025 | Zoryve |
| Incyte Corporation | $7,735.85 | 2021-2025 | Opzelura |
| Organon LLC | $7,631.33 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $6,075.20 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $3,494.05 | 2020-2025 | |
| Dermavant Sciences, INC. | $3,107.62 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $2,734.86 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,321.91 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $974.08 | 2019-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $961.20 | 2019-2021 | |
| Galderma Laboratories, L.P. | $723.08 | 2019-2025 | Nemluvio, Aklief |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Costner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.